Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Renal Disease Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLC13A2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC13A2 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View SLC13A2 Products |
| Gene Delivery | SLC13A2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional transport assays. |
View SLC13A2 Products |
| Benchmark Ab | Anti-SLC13A2 Benchmark Antibody Recombinant positive control for expression validation. |
View SLC13A2 Products |
| Validator | SLC13A2 siRNA Set For target knockdown and specificity verification. |
View SLC13A2 Products |
| Related Target A | SLC13A5 Highly homologous sodium-coupled citrate transporter; critical for off-target selectivity screening. |
View SLC13A5 Products |
| Related Target B | SLC13A3 Sodium-coupled dicarboxylate transporter 2; essential for subfamily cross-reactivity profiling. |
View SLC13A3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass Membrane Target Conformation | Lentivirus-driven mammalian expression ensures native 11-transmembrane folding in host cells. |
| Subfamily Off-Target Screening | Matched SLC13 family panels (SLC13A3, SLC13A5) available for parallel selectivity profiling. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included. |
| False Positives in Transport Inhibition | Validated siRNA sets included for target-specific knockdown verification. |
Live SLC13A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLC13A2 therapeutics is intensifying, with major players shifting focus from traditional systemic metabolic modulation to tissue-specific transport inhibition. As first-generation small molecule inhibitors enter preclinical optimization, the next wave of R&D is targeting high-affinity monoclonal antibodies and cell-based functional assays to overcome selectivity hurdles within the SLC13 family.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Kidney Stones, Hypocitraturia, Gout | Functional Transport Assay (Need Lentivirus for Stable Cell Line) |
| Monoclonal Antibodies | Biopharma Innovators | Renal Metabolic Disorders | Conformational Epitope Binding (Need Sequence-Verified Antigens) |
| RNA Therapeutics | Gene Therapy Pioneers | Hyperoxaluria, Nephrolithiasis | Knockdown Validation (Need High-Purity siRNA Sets) |